George Armah1, Kimberly Pringle2, Christabel C Enweronu-Laryea3, Daniel Ansong4, Jason M Mwenda5, Stanley K Diamenu6, Clement Narh7, Belinda Lartey1, Fred Binka8, Scott Grytdal2, Manish Patel2, Umesh Parashar2, Ben Lopman2. 1. Noguchi Memorial Institute for Medical Research, University of Ghana, Accra. 2. Centers for Disease Control and Prevention, Atlanta, Georgia. 3. School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra. 4. Komfo Anokye Teaching Hospital, Kumasi, Ghana. 5. World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo. 6. Ghana World Health Organization Country Office, Accra. 7. Noguchi Memorial Institute for Medical Research, University of Ghana, Accra School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana. 8. School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.
Abstract
BACKGROUND: Ghana was among the first African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization schedule in April 2012. We aimed to assess the impact of vaccine introduction on rotavirus and acute gastroenteritis (AGE) hospitalizations and to estimate vaccine effectiveness (VE). METHODS: Using data from 2 teaching hospitals, monthly AGE and rotavirus admissions by age were examined 40 months before and 31 months after RV1 introduction using interrupted time-series analyses. From January 2013, we enrolled children <2 years of age who were eligible for RV1 from a total of 7 sentinel sites across the country. To estimate VE, we fit unconditional logistic regression models to calculate odds ratios of vaccination by rotavirus case-patient status, controlling for potential confounders. RESULTS: Vaccine coverage ranged from 95% to 100% for dose 1 and 93% to 100% for dose 2. In the first 3 years after vaccine introduction, the percentage of hospital admissions positive for rotavirus fell from 48% in the prevaccine period to 28% (49% adjusted rate reduction; 95% confidence interval [CI], 32%-63%) postvaccination among <5-year-olds. With high vaccine coverage, it was not possible to arrive at robust VE estimates; any-dose VE against rotavirus hospitalization was estimated at 60% (95% CI, -2% to 84%;P= .056). CONCLUSIONS: Results from the first 3 years following RV1 introduction suggest substantial reductions of pediatric diarrheal disease as a result of vaccination. Our VE estimate is consistent with the observed rotavirus decrease and with efficacy estimates from elsewhere in sub-Saharan Africa. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Ghana was among the first African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization schedule in April 2012. We aimed to assess the impact of vaccine introduction on rotavirus and acute gastroenteritis (AGE) hospitalizations and to estimate vaccine effectiveness (VE). METHODS: Using data from 2 teaching hospitals, monthly AGE and rotavirus admissions by age were examined 40 months before and 31 months after RV1 introduction using interrupted time-series analyses. From January 2013, we enrolled children <2 years of age who were eligible for RV1 from a total of 7 sentinel sites across the country. To estimate VE, we fit unconditional logistic regression models to calculate odds ratios of vaccination by rotavirus case-patient status, controlling for potential confounders. RESULTS: Vaccine coverage ranged from 95% to 100% for dose 1 and 93% to 100% for dose 2. In the first 3 years after vaccine introduction, the percentage of hospital admissions positive for rotavirus fell from 48% in the prevaccine period to 28% (49% adjusted rate reduction; 95% confidence interval [CI], 32%-63%) postvaccination among <5-year-olds. With high vaccine coverage, it was not possible to arrive at robust VE estimates; any-dose VE against rotavirus hospitalization was estimated at 60% (95% CI, -2% to 84%;P= .056). CONCLUSIONS: Results from the first 3 years following RV1 introduction suggest substantial reductions of pediatric diarrheal disease as a result of vaccination. Our VE estimate is consistent with the observed rotavirus decrease and with efficacy estimates from elsewhere in sub-Saharan Africa. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245
Authors: Naor Bar-Zeev; Lester Kapanda; Jacqueline E Tate; Khuzwayo C Jere; Miren Iturriza-Gomara; Osamu Nakagomi; Charles Mwansambo; Anthony Costello; Umesh D Parashar; Robert S Heyderman; Neil French; Nigel A Cunliffe Journal: Lancet Infect Dis Date: 2015-01-29 Impact factor: 25.071
Authors: Christabel C Enweronu-Laryea; Isaac Boamah; Eric Sifah; Stanley K Diamenu; George Armah Journal: BMC Infect Dis Date: 2014-08-06 Impact factor: 3.090
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Christabel C Enweronu-Laryea; George Armah; Kwamena W Sagoe; Daniel Ansong; Emmanuel Addo-Yobo; Stanley K Diamenu; Jason M Mwenda; Umesh D Parashar; Jacqueline E Tate Journal: Vaccine Date: 2018-05-08 Impact factor: 3.641
Authors: Amadou Diop; Aliou Thiongane; Jason M Mwenda; Negar Aliabadi; Mouhamadou A Sonko; Aliou Diallo; Babacar Ndoye; Papa M Faye; Idrissa D Ba; Umesh D Parashar; Jacqueline E Tate; Ousmane Ndiaye; Moussa F Cissé; Mamadou Ba Journal: Vaccine Date: 2017-11-20 Impact factor: 3.641